Search

(GLOBE NEWSWIRE via COMTEX) -- - The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of [...]

(GLOBE NEWSWIRE via COMTEX) -- Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3KaY signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 [...]

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA(R) (pembrolizumab) showed promising efficacy data with partial responses in [...]

(GLOBE NEWSWIRE via COMTEX) -- - Novel JEL(TM) Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that [...]

Novel JEL(TM) Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed [...]

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates [...]

BEIJING, August 15, 2024 (Xinhua via COMTEX) -- A new injection, which is an mRNA vaccine for Epstein-Barr virus positive tumors, has been approved by the Center for Drug Evaluation [...]

14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment resulted in continued, [...]

100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at [...]

SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global development and commercialization [...]

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ('AEON' or the 'Company') (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for [...]

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ('ImmixBio', 'Company', 'We' or 'Us' or 'IMMX'), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL [...]

ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial [...]

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% [...]

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after [...]

- Expect to announce topline data in Q3 2024 - - Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in [...]

The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12 The significant improvement in lung function was observed as early [...]

HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech's Divarasib plus Cetuximab study [...]

SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ('Connect Biopharma' or the 'Company'), a global clinical-stage biopharmaceutical company dedicated to [...]

(GLOBE NEWSWIRE via COMTEX) -- - Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, [...]

Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial [...]

HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ('Benitec' or the 'Company'), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its [...]

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) [...]

(GLOBE NEWSWIRE via COMTEX) -- - NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance - 72 patients previously dosed with NXC-201 [...]

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 [...]

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level [...]

(GLOBE NEWSWIRE via COMTEX) -- - Data from Evaxion's two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) [...]

Data from Evaxion's two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) These new sets of clinical data [...]

(GLOBE NEWSWIRE via COMTEX) -- - Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease - Additional late-breaking presentations from the CLARITY [...]

- ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) [...]

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting A Gilead-led Phase 1 clinical trial [...]

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) [...]

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 [...]

HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine [...]

BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ('First Wave BioPharma' or the 'Company'), a clinical-stage biopharmaceutical company specializing in the development of targeted, [...]

BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ('First Wave BioPharma' or the 'Company'), a clinical-stage biopharmaceutical company specializing in the development of targeted, [...]

This press release contains 'forward-looking statements.' Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential,' or similar words. [...]

Auger electron and beta emitting isotope terbium-161 was paired with POINT's FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555 Preclinical proof-of-concept established for [...]

HAYWARD, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ('Benitec' or 'Company'), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary [...]

Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning [...]

Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period. Icanbelimod continued [...]

ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo Cytisinicline demonstrated 6x increase in odds [...]

Novel JEL(TM) Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 [...]

(GLOBE NEWSWIRE via COMTEX) -- - Novel JEL(TM) Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that [...]

8 AL Amyloidosis patients relapsed/refractory to DARZALEX(R)-based regimens were treated with CAR-T NXC-201 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10[sup.-5]) was demonstrated by NXC-201 with [...]

Top line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ('First Wave BioPharma' or the 'Company') (NASDAQ: FWBI), [...]

100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort (two out [...]

Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE [...]

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=gqpCLkH_WfDOgMGBrvJRN2HXfG_tl26VR_M34TUZ1pWjpdxsD9jdC0EYzsuyv2wSHC0dk6CI_dpQ9lIePFpvlQ== (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option [...]

(GLOBE NEWSWIRE via COMTEX) -- - Pivotal Phase 3 trial of MVA-BN(R) RSV has accrued enough cases required for efficacy analysis - Topline results expected around mid-2023 COPENHAGEN, Denmark, April [...]